Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis

• Published in: World journal of gastroenterology : WJG Vol. 13; no. 11; pp. 1666 - 1671
• Main Authors: Hirata, Ichiro, Yasumoto, Shingo, Toshina, Ken, Inoue, Takuya, Nishikawa, Takashi, Murano, Naoko, Murano, Mitsuyuki, Wang, Fang-Yu, Katsu, Ken-ichi
• Format: Journal Article
• Language: English
• Published: United States Department of Gastroenterology, Fujita Health University, Japan%Second Department of Internal Medicine, Osaka Medical College, Japan%Department of Gastroenterology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, Jiangsu Province, China 21.03.2007; Baishideng Publishing Group Co., Limited
• Subjects: Animals; Antioxidants - administration & dosage; Antioxidants - pharmacology; Basic Research; Colitis - chemically induced; Colitis - drug therapy; Colitis - pathology; Colon - metabolism; Colon - pathology; Dextran Sulfate; Disease Models, Animal; Female; Indicators and Reagents; Inflammation - chemically induced; Inflammation - drug therapy; Inflammation - pathology; Injections, Intraperitoneal; Interleukin-1beta - metabolism; Mice; Mice, Inbred BALB C; NF-kappa B - metabolism; PDTC; Pyrrolidines - administration & dosage; Pyrrolidines - pharmacology; Severity of Illness Index; Thiocarbamates - administration & dosage; Thiocarbamates - pharmacology; Tumor Necrosis Factor-alpha - metabolism; 右旋糖苷硫酸钠盐; 四氢吡咯二硫代氨基甲酸酯; 抑制作用; 诱发大肠炎; NF-κB; DSS-induced colitis; Mice; Pyrrolidine dithiocarbamate; Ulcerative colitis
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v13.i11.1666

AIM： TO evaluate the effect of pyrrolidine dithiocarbamate （PDTC; an NF-κB inhibitor） administered at low （50 mg/kg） and high （100 mg/kg） doses in suppressing colitis in mice with dextran sodium sulfate （DSS）-induced colitis. METHODS： Mice were divided into a DSS-untreated group （normal group）, DSS-treated control group, DSS＋PDTC-treated group Ⅰ （low-dose group）, and DSS＋PDTC-treated group Ⅱ （high-dose group）. In each group, the disease activity index score （DAI score）, intestinal length, histological score, and the levels of activated NF-κB and inflammatory cytokines （IL-1β and TNF-α） in tissue were measured. RESULTS： The DSS＋PDTC-treated group Ⅱ exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels were significantly lower in DSS＋PDTC- treated group Ⅱ. CONCLUSION： These findings suggest that PDTC is useful for the treatment of ulcerative colitis.